Agios Pharmaceuticals AGIO is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for thalassemia in the United States. Outside the United States, mitapivat continues to be marketed as Pyrukynd for both indications. Agios is also seeking to expand mitapivat into sickle cell disease (SCD). However, setbacks in its pipeline and growing competition in SCD have increased the company's reliance on mitapivat's commercial performance. Mitapivat Products Drive Agios' Top-line Growth Agios' commercial momentum accelerated in January 2026 following the U.S.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.